Valneva Submits Label Extension Application for its Chikungunya Vaccine, IXCHIQ®, to the U.S. FDA
Portfolio Pulse from
Valneva SE has submitted a label extension application to the U.S. FDA for its chikungunya vaccine, IXCHIQ®, to include adolescents and two-year antibody persistence data.
November 26, 2024 | 5:00 pm
News sentiment analysis
Sort by:
Ascending
POSITIVE IMPACT
Valneva SE has applied to the FDA to extend the use of its chikungunya vaccine IXCHIQ® to adolescents and include two-year antibody persistence data, potentially expanding its market.
The submission to the FDA for a label extension could lead to an expanded market for IXCHIQ® if approved, potentially increasing Valneva's revenue. The inclusion of two-year antibody persistence data strengthens the product's competitive position.
CONFIDENCE 90
IMPORTANCE 80
RELEVANCE 90